176 related articles for article (PubMed ID: 31658877)
1. How oncogenic mutations activate human MAP kinase 1 (MEK1): a molecular dynamics simulation study.
Liu Y; Zhu J; Guo X; Huang T; Han J; Gao J; Xu D; Han W
J Biomol Struct Dyn; 2020 Aug; 38(13):3942-3958. PubMed ID: 31658877
[TBL] [Abstract][Full Text] [Related]
2. Allosteric Kinase Inhibitors Reshape MEK1 Kinase Activity Conformations in Cells and In Silico.
Fleischmann J; Feichtner A; DeFalco L; Kugler V; Schwaighofer S; Huber RG; Stefan E
Biomolecules; 2021 Mar; 11(4):. PubMed ID: 33808483
[TBL] [Abstract][Full Text] [Related]
3. Computational Study on the Effect of Inactivating/Activating Mutations on the Inhibition of MEK1 by Trametinib.
Zhu J; Li C; Yang H; Guo X; Huang T; Han W
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32245216
[TBL] [Abstract][Full Text] [Related]
4. Increase in constitutively active MEK1 species by introduction of MEK1 mutations identified in cancers.
Kinoshita-Kikuta E; Kinoshita E; Ueda S; Ino Y; Kimura Y; Hirano H; Koike T
Biochim Biophys Acta Proteins Proteom; 2019 Jan; 1867(1):62-70. PubMed ID: 29753091
[TBL] [Abstract][Full Text] [Related]
5. Constitutively active MAP kinase kinase (MEK1) stimulates SAP kinase and c-Jun transcriptional activity in U937 human leukemic cells.
Franklin CC; Kraft AS
Oncogene; 1995 Dec; 11(11):2365-74. PubMed ID: 8570188
[TBL] [Abstract][Full Text] [Related]
6. Mek1 phosphorylation site mutants activate Raf-1 in NIH 3T3 cells.
Alessandrini A; Greulich H; Huang W; Erikson RL
J Biol Chem; 1996 Dec; 271(49):31612-8. PubMed ID: 8940180
[TBL] [Abstract][Full Text] [Related]
7. Constitutively active mutant of the mitogen-activated protein kinase kinase MEK1 induces epithelial dedifferentiation and growth inhibition in madin-darby canine kidney-C7 cells.
Schramek H; Feifel E; Healy E; Pollack V
J Biol Chem; 1997 Apr; 272(17):11426-33. PubMed ID: 9111053
[TBL] [Abstract][Full Text] [Related]
8. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition.
Ohren JF; Chen H; Pavlovsky A; Whitehead C; Zhang E; Kuffa P; Yan C; McConnell P; Spessard C; Banotai C; Mueller WT; Delaney A; Omer C; Sebolt-Leopold J; Dudley DT; Leung IK; Flamme C; Warmus J; Kaufman M; Barrett S; Tecle H; Hasemann CA
Nat Struct Mol Biol; 2004 Dec; 11(12):1192-7. PubMed ID: 15543157
[TBL] [Abstract][Full Text] [Related]
9. Computational targeting of allosteric site of MEK1 by quinoline-based molecules.
Singh R; Bhardwaj VK; Purohit R
Cell Biochem Funct; 2022 Jul; 40(5):481-490. PubMed ID: 35604288
[TBL] [Abstract][Full Text] [Related]
10. Identification of novel point mutations in ERK2 that selectively disrupt binding to MEK1.
Robinson FL; Whitehurst AW; Raman M; Cobb MH
J Biol Chem; 2002 Apr; 277(17):14844-52. PubMed ID: 11823456
[TBL] [Abstract][Full Text] [Related]
11. MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas.
Murugan AK; Dong J; Xie J; Xing M
Cell Cycle; 2009 Jul; 8(13):2122-4. PubMed ID: 19411838
[TBL] [Abstract][Full Text] [Related]
12. MEK1 inhibits cardiac PPARĪ± activity by direct interaction and prevents its nuclear localization.
el Azzouzi H; Leptidis S; Bourajjaj M; van Bilsen M; da Costa Martins PA; De Windt LJ
PLoS One; 2012; 7(6):e36799. PubMed ID: 22723831
[TBL] [Abstract][Full Text] [Related]
13. Characterization of Activating Mutations of the
Borrelli N; Panebianco F; Condello V; Barletta JA; Kaya C; Yip L; Nikiforova MN; Nikiforov YE
Thyroid; 2019 Sep; 29(9):1279-1285. PubMed ID: 31407636
[No Abstract] [Full Text] [Related]
14. BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.
Emery CM; Monaco KA; Wang P; Balak M; Freeman A; Meltzer J; Delach SM; Rakiec D; Ruddy DA; Korn JM; Haling J; Acker MG; Caponigro G
Mol Cancer Res; 2017 Oct; 15(10):1431-1444. PubMed ID: 28655712
[TBL] [Abstract][Full Text] [Related]
15. Transfection of constitutively active mitogen-activated protein/extracellular signal-regulated kinase kinase confers tumorigenic and metastatic potentials to NIH3T3 cells.
Welch DR; Sakamaki T; Pioquinto R; Leonard TO; Goldberg SF; Hon Q; Erikson RL; Rieber M; Rieber MS; Hicks DJ; Bonventre JV; Alessandrini A
Cancer Res; 2000 Mar; 60(6):1552-6. PubMed ID: 10749122
[TBL] [Abstract][Full Text] [Related]
16. Mitogen-activated protein kinase (MAPK)-docking sites in MAPK kinases function as tethers that are crucial for MAPK regulation in vivo.
Grewal S; Molina DM; Bardwell L
Cell Signal; 2006 Jan; 18(1):123-34. PubMed ID: 15979847
[TBL] [Abstract][Full Text] [Related]
17. PAK1 primes MEK1 for phosphorylation by Raf-1 kinase during cross-cascade activation of the ERK pathway.
Coles LC; Shaw PE
Oncogene; 2002 Mar; 21(14):2236-44. PubMed ID: 11948406
[TBL] [Abstract][Full Text] [Related]
18. How activating mutations affect MEK1 regulation and function.
Jindal GA; Goyal Y; Humphreys JM; Yeung E; Tian K; Patterson VL; He H; Burdine RD; Goldsmith EJ; Shvartsman SY
J Biol Chem; 2017 Nov; 292(46):18814-18820. PubMed ID: 29018093
[TBL] [Abstract][Full Text] [Related]
19. Conformational Dynamics Analysis of MEK1 Using Hydrogen/Deuterium Exchange Mass Spectrometry.
Yun MW; Kim K; Park JY; Chung KY
Protein Pept Lett; 2021; 28(5):481-488. PubMed ID: 33143608
[TBL] [Abstract][Full Text] [Related]
20. Trametinib in the treatment of multiple malignancies harboring MEK1 mutations.
Lian T; Li C; Wang H
Cancer Treat Rev; 2019 Dec; 81():101907. PubMed ID: 31715422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
